This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Fresenius Sued Again In Cardiac Death Lawsuit

BOSTON, Feb. 28, 2013 /PRNewswire/ -- Nix Patterson and Roach, LLP and Feazell & Tighe LLP announce the filing of a wrongful death lawsuit against the manufacturer of GranuFlo®, Fresenius Medical Care North America.  The lawsuit was filed in Boston federal court on February 27, 2013, by Bettye Alexander, whose late husband Gary Alexander suffered a heart attack and died following hemodialysis treatment using GranuFlo®.  Mrs. Alexander alleges that Fresenius failed to warn that GranuFlo®, which has been used as part of a dialysate prescription at thousands of dialysis clinics over the last decade, puts patients at a substantially higher risk of cardiac arrest, stroke, and sudden cardiac death. 

Nix Patterson & Roach, LLP and Feazell & Tighe LLP currently represent more than 1300 people alleged to have suffered cardiac arrest, stroke, or sudden cardiac death following the use of GranuFlo® or a similar Fresenius dialysate product, NaturaLyte®

The lawsuit alleges that Fresenius was aware of the risk for years, long before Mr. Alexander underwent his hemodialysis treatment.  An internal memo written by Fresenius in November 2011 warned that the use of GranuFlo® was associated with a 6 to 8 fold greater increase of cardiopulmonary arrest and sudden cardiac death in the dialysis facility.  That internal memo, which covered only a single year and a third of Fresenius's clinics, identified 947 cardiac deaths.  Fresenius sent that internal memo to its own network of dialysis clinics.  But Fresenius sells GranuFlo® to thousands of other dialysis clinics as well.  It did not share this information with any of them until almost five months later.  The internal memo was leaked anonymously to the FDA in March, 2012, and a recall of GranuFlo® and a similar product, NaturaLyte®, was issued later that month.  For more information on the recall, please visit http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm

Mrs. Alexander, who is also represented by Kreindler & Kreindler LLP, seeks compensatory and punitive damages for the unnecessary and unfortunate death of her husband.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs